Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
![Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby](https://g.foolcdn.com/editorial/images/462512/doctor-patient.jpg)
Exelixis (NASDAQ: EXEL), the biotech once left for dead by quite a few investors, continues its resurgence with another solid quarter of sales of its kidney cancer drug Cabometyx. Of course, the third quarter almost doesn't matter that much since most of the biotech's current valuation is supported by potential future sales as Exelixis hopes to expand drug treatment of first-line kidney cancer as well as liver cancer.
Metric
Q3 2017
Source: Fool.com
Exelixis Inc. Stock
€23.23
-0.260%
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
As a result the target price of 26 € shows a slightly positive potential of 11.92% compared to the current price of 23.23 € for Exelixis Inc..